23 May 2025, Mumbai – Kilitch Drugs Limited, BSE and NSE listed, a leading pharmaceutical company specializing in the manufacturing and distribution of high-quality Parenteral, Injectables, Oral Solids, and Effervescent, announced its unaudited financial results for the quarter ended on 31 March 2025

The company’s reported a 178% per cent year-on-year(Y-o-Y) remarkable rise in consolidated profit after tax (PAT) for the Q4 FY25 to Rs. 1,021.86 lakh from Rs. 368.07 lakh for the corresponding period previous year.

The company recorded its quarterly consolidated revenue from operations at Rs. 6,122.58 lakh in Q4FY25, experiencing 37 per cent of Y-o-Y excellence growth from Rs. 4,481.88 lakh in Q4FY24. The growth is achieved by continuous efforts to meet steady demand across globe and will continue further.

Consecutively, the company’s standalone PAT rose by 212%% per cent, and revenue grew by 44% per cent to Rs 1,137.41 lakh and Rs 18,158.73 lakh recorded in Q4 FY25, respectively.

For the year ending March 2025, In FY25, Kilitch reported an over 77 percent YoY rise in standalone net profit to ₹ 3,115.69 lakh, compared to ₹ 1,757.38 lakh in FY24. The Standalone Revenue from operation for the period increased by 38 percent to ₹Rs 18,158.73 lakh from ₹Rs 13,159.90 lakh in the previous year.

Commenting on the Q4FY25 performance, Mr. Mukund Mehta, the Managing Director of Kilitch Drugs said, “We witnessed significant growth in our performance for this year; revenue from operations grew by 44% and PAT increased by 212% on standalone basis as compared to Q4FY2024. We remain focused on driving sustainable growth and delivering strong returns for our stakeholders.”